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HPV-related HNSCC generally have a better prognosis than HPV-negative HNSCC. However, a subgroup of HPV-positive tumors with
poor prognosis has been recognized, particularly related to smoking, EGFR overexpression and chromosomal instability. Viral integra-
tion into the host genome might contribute to carcinogenesis, as is shown for cervical carcinomas. Therefore, all HPV16-positive
HNSCC cell lines currently available have been carefully analyzed for viral and host genome parameters. The viral integration status,
viral load, viral gene expression and the presence of aneusomies was evaluated in the cell lines UD-SCC-2, UM-SCC-047, UM-SCC-104,
UPCI:SCC090, UPCI:SCC152, UPCI:SCC154 and 93VU147T. HPV integration was examined using FISH, APOT-PCR and DIPS-PCR. Viral
load and the expression of the viral genes E2, E6 and E7 were determined via quantitative PCR. All cell lines showed integration-
specific staining patterns and signals indicating transcriptional activity using FISH. APOT- and DIPS-PCR identified integration-derived
fusion products in six cell lines and only episomal products for UM-SCC-104. Despite the observed differences in viral load and the
number of viral integration sites, this did not relate to the identified viral oncogene expression. Furthermore, cell lines exhibited EGFR
expression and aneusomy (except UPCI:SCC154). In conclusion, all HPV16-positive HNSCC cell lines showed integrated and/or episo-
mal viral DNA that is transcriptionally active, although viral oncogene expression was independent of viral copy number and the num-
ber of viral integration sites. Because these cell lines also contain EGFR expression and aneusomy, which are parameters of poor
prognosis, they should be considered suitable model systems for the development of new antiviral therapies.
Infection with high-risk human papillomavirus (HPV) is a
causative factor for the development of several types of neo-
plasms, including cervical, anogenital and a subset of head
and neck cancers. Although most head and neck squamous
cell carcinomas (HNSCC) can be attributed to the exposure
to environmental factors, such as excessive tobacco and
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alcohol use, 20–25% of these cancers are caused by infec-
tion with HPV16. Notably, HPV-induced tumors are prefer-
entially found in the oropharynx, where up to 90% of the
malignancies are associated with HPV.1–3
Patients with HPV-induced carcinomas display clinical and
molecular characteristics that are distinct from those in patients
with tobacco- and alcohol-induced tumors. It is now well
accepted that patients with HPV-derived tumors have a favour-
able prognosis, independent of the chosen treatment strategy.4–6
As first described by Ang et al.,7 HNSCC can be divided
into three risk groups, depending on HPV status, the number
of pack-years (<10 vs. >10) of tobacco smoking and nodal
stage (N0-N2a vs. N2b-N3). In addition, it was shown that
EGFR overexpression negatively affects overall survival both
in HPV-positive as well as in HPV-negative tumors.4 Chro-
mosomal instability was also reported to have a negative
influence on prognosis, especially in HPV-positive tumors.8
These data indicate that smoking, advanced nodal stage,
EGFR overexpression and chromosomal instability are risk
parameters for poor prognosis in HPV-associated HNSCC.
From uterine cervical (pre)malignancy models it is
hypothesized that integration of HPV into the host genome
plays an important role in the carcinogenic process. It corre-
lates with the severity and progression of these lesions and is
considered a risk factor for the development of uterine cervi-
cal squamous cell carcinoma.9,10 In addition, a higher viral
load is associated with higher grade lesions. It is, however,
not possible to predict tumor progression based on the inte-
gration status of HPV or the viral load.11
HNSCC, in particular oropharyngeal squamous cell carci-
nomas, are mostly discovered as metastatic disease and data
on premalignant lesions are scarce. Therefore limited infor-
mation is available on the role of viral integration in the
development of these tumors. It is hypothesized, however,
that viral integration also promotes carcinogenesis in
HNSCC, but this is not substantiated by clinical studies on
premalignant lesions, as is the case for cervical lesions.
Furthermore, the reported integration percentages in
HNSCC vary considerably, ranging from 0% to almost 100%
in different publications.1,12–15 This extreme variation might
be explained by the different patient populations studied, the
different methods applied to study viral integration and a
lack of correlation between these methods.
However, the integration status of the virus can be of
significance in relation to treatment. Chang et al.16 and
Herdman et al.17 have shown a clear difference in the
response of keratinocytes with episomal versus integrated
HPV. Using these cell line models it could be shown that
interferon therapy can eradicate episomal HPV infection, but
leads to a growth advantage for cells containing integrated
HPV. This indicates that antiviral therapies might be influ-
enced by the viral integration status. Thus, it is imperative to
have a well-characterized model for HPV-associated HNSCC,
for which the physical status of the virus is known.
This study presents a detailed analysis of the integration
status in 7 HPV-positive HNSCC cell lines established from
HPV-induced tumors. The integration status has been assessed
using a set of independent techniques, that is, DNA and RNA
FISH, APOT- and DIPS-PCR. In addition, the expression lev-
els of the viral genes E2, E6 and E7 and the expression levels of
EGFR, as well as the viral load were analyzed.
Material and Methods
Cell lines
Human HPV16-positive HNSCC cell lines were obtained
from different sources. Cell lines UPCI:SCC090,
UPCI:SCC152 and UPCI:SCC154 were kindly provided by
Dr. Susanne Gollin from the University of Pittsburgh, Pitts-
burgh, PA. The UPCI:SCC152 cell line was established from
a recurrence in the patient from which the cell line
UPCI:SCC090 was derived.18 Cell line UD-SCC-2 was a kind
gift from Dr. Thomas Hoffmann; present address University
of Ulm, Germany.19 The cell lines UM-SCC-047 and UM-
SCC-104 were a kind gift from Dr. Thomas Carey, University
of Michigan, Ann Arbor, MI. The cell line 93VU147T was
provided by Dr. J.P. de Winter, Free University Medical
Centre, Amsterdam, The Netherlands.20 Clinicopathological
data of the patients and tumors from which the cell lines
were derived are given in Table 1.
Cell lines UD-SCC-2 and 93VU147T were cultured in MEM
(Invitrogen, Carlsbad, CA) containing 10% FCS (Sigma, St Louis,
MO), 2 mM glutamine (Invitrogen), 0.1 mM MEM nonessential
amino acids (Invitrogen) and 0.005% gentamycin (Eurovet Ani-
mal Health BV, Bladel, The Netherlands). The remaining cell
lines were cultured in DMEM (Invitrogen) containing the same
additives as described above. Cell lines UM-SCC-047, UPCI:
SCC090 and UD-SCC-2 were received in 2008 and UM-SCC-
104, UPCI:SCC152, UPCI:SCC154 and 93VU147T in 2011 and
were frozen immediately upon arrival. All cell lines were con-
firmed to have unique genotypes, as tested using the ProfilerPlus
assay, except the cell lines UPCI:SCC090 and UPCI:SCC152,
which shared the same genotype as they are derived from the
What’s new?
High-risk human papillomavirus (HPV) infection is a well-established risk factor for head and neck squamous cell carcinoma
(HNSCC) development. It is still unclear however whether viral DNA integration into the host genome plays an important role
in HPV carcinogenesis in HNSCC. In this study, seven HPV16-positive HNSCC cell lines showed integrated and/or episomal
viral DNA that is transcriptionally active. Both viral load and expression of several viral early genes were variable. Because the
cell lines also feature EGFR overexpression and aneusomy, which are parameters of poor prognosis, they may represent suita-
ble model systems for the development of new antiviral therapies.
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same patient (see Supporting Information Table S1). Cell lines in
culture were regularly tested for infection with mycoplasma.
The uterine cervical cancer cell lines SiHa and CaSki were
used as HPV16- and p16INK4A-positive controls in p16INK4A
immunostaining and HPV16-specific PCR analysis. The uter-
ine cervical cancer cell line HeLa, the HPV-negative HNSCC
cell line UPCI:SCC003 and the osteosarcoma cell line U2OS
containing the empty pJ4X-vector21 were used as negative
controls in these assays. The latter cell line harbouring
HPV16-E2-containing pJ4X-vector was used as a positive
control for HPV16-E2 RT-PCR and immunohistochemistry.
DNA/RNA extraction
DNA was isolated from cultured cells using QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) as per the manu-
facturers’ instructions. Total RNA was extracted using the
RNeasy mini kit (Qiagen) according to the manufacturer’s
instructions, including DNase treatment. RNA concentration
and quality were determined by RNA standard sense chips
on a BioRad Experion system (BioRad, Munich, Germany).
HPV DNA PCR
The presence of HPV DNA was detected by PCR using the
consensus primer set GP51/61,22 followed by type-specific pri-
mers for HPV16 and HPV18. The following primers were used:
Target Primer Sequence
HPV16 Forward 50-ACAGGAGCGACCCAGAAAGTTAC-30
Reverse 50 GCATAAATCCCGAAAAGCAAAGT-30
HPV18 Forward 50-CACATTGGAAAAACTAACTAACACACTGG-30
Reverse 50-CAGCTATGTTGTGAAATCGTCGTT-30
Primers were synthesized by Biolegio BV, Nijmegen, The
Netherlands. Five microliter of PCR product were separated
on a 1.5 % agarose gel and visualized using GelStar Nucleic
Acid Gel Stain (Cambrex Bio Science Rockland).
Viral load
Viral load of HPV16 was determined using real-time fluores-
cence PCR with type-specific primers and probes as described
earlier.23 Briefly, viral load was expressed as the number of
HPV16 DNA copies per b-globin-gene copy. Gene copy num-
bers of b-globin were determined using the LightCycler-
Control Kit DNA (Roche Molecular Biochemicals) according
to the manufacturer’s instructions as previously described.24
Calculation of initial copy numbers in samples was performed
by the LightCycler 480 software (Version 1.5) using a standard
curve generated with exactly quantified HPV DNA standards
(ten-fold dilution series of full length HPV16 plasmid) that
were amplified in the same PCR run.23,24 The analytical sensi-
tivity of the assay was 10 copies of HPV16 standard DNA. A
negative control (water or DNA extracted from RTS3B cells
that are negative for HPV) was included in each run and never
yielded fluorescence signals above the background.25
Viral integration analysis
DNA and RNA fluorescence in situ hybridization. HPV16-spe-
cific probes were purchased from PanPath, Amsterdam, The Neth-
erlands. BAC-clones, used for colocalization experiments, were
grown according to the manufacturer’s instructions (BACPAC
Resources Centre, Childrens Hospital Oakland Research Institute,
Oakland). DNA was isolated using the Nucleobond BAC-100 kit
(BioKe, Leiden, The Netherlands). Probes for centromeres (CEPs)
1, 3 and 9 were available in our lab, previously described in Hop-
man et al.26 Probes and clones were labelled using either the Dig-
nick translation kit or the Biotin-nick translation kit (Roche, Basel,
Switzerland), according to the manufacturer’s instructions. Labeled
CEP probes for CEP17 and CEPX were kindly provided by the
Department of Clinical Genetics, Maastricht University Medical
Centre, Maastricht, The Netherlands. To exclude possible hybrid-
ization to RNA transcripts, cells were treated with 10 ng/ml ribonu-
clease A (Qiagen) in a control experiment.
DNA FISH. Fluorescence in situ hybridisation (FISH) was per-
formed as described earlier.12,27 Briefly, cells were fixed in 70%
ethanol, incubated with 0.01% pepsin (800–1200 U/mg protein
from porcine stomach mucosa; Sigma) in 0.01N HCl and post-
fixed in 1% formaldehyde in PBS. Probe and target DNA were
denatured simultaneously for 3 min at 80C prior to hybridiza-
tion overnight at 37C in a humid chamber. After hybridization,
the preparations were washed stringently. Biotin-labeled probe
was detected using FITC-conjugated-avidine (Vector Laborato-
ries, Burlingame, CA), biotin-conjugated goat-anti-avidin
Table 1. Characteristics of patients from which the cell lines have been derived
Cell line UD-SCC-2 UM-SCC-47 UM-SCC-104 UPCI:SCC090 UPCI:SCC152 UPCI:SCC154 93VU147T
M/F M M M M M M M
Age at diagnosis 58 53 56 46 47 54 58
Smoking y y y y y y y
Alcohol y n.a. y y y y y
Primary tumor site hypo-pharynx lateral tongue floor of mouth base of tongue hypo-pharynx tongue floor of mouth
TNM T1N3 T3N1M0 T4N2bM0 T2N0 recurrence T4N2 T4N2
Differentiation n.a. M/W P/M P M n.a. M
Abbreviations: M: Male; F: Female; n.a.: not available; W: well differentiated; M: medium differentiated; P: poorly differentiated.
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(Vector) and again FITC-conjugated-avidin. In cases where two
hybridization probes were used simultaneously, biotin-labeled
probes were detected as described above. The digoxigenin-
labeled probe was detected using mouse-anti-digoxigenin,
TRITC-conjugated rabbit-anti-mouse and finally TRITC-
conjugated swine-anti-rabbit (all from Dako, Glostrup, Den-
mark). Slides were mounted in Vectashield (Vector) containing
40,6-diamidino-2-phenylindole (DAPI; Sigma).
RNA FISH. The HPV16 RNA specific FISH was performed on
CytoRichRed-fixed, paraffin-embedded slides of the different
cell lines according to Smedts et al.28 or on 70% ethanol sus-
pensions additionally fixed in CytoRichRed. In contrast to
DNA FISH, cells were rehydrated in an ethanol series using
RNAse block (Biogenex) in the 50% ethanol and demineral-
ized water solutions, digested with proteinase K (DAKO PNA
ISH detection kit) for 20 min at RT and hybridized with dena-
tured digoxigenin-labeled HPV16 DNA probes. Cells were not
denatured to allow hybridization to viral RNA and to prevent
hybridization to viral DNA. After overnight hybridization, the
slides were processed according to the FISH protocol described
above. As a negative control, slides were treated with RNAse.
Images were acquired using a Leica DMRXA microscope
(Leica, Wetzlar, Germany) equipped with optical filters for
DAPI, fluorescein and TRITC and a 633 Plan Apo (NA
1.32) objective. The microscope was connected to a digital
black and white CCD camera (Metasystems Image Pro Sys-
tem, Sandhausen, Germany) for image recording. Staining
patterns were scored as described earlier.29
Metaphase spreads. Metaphase spreads were made as
described previously,30 with minor adjustments. Briefly, cells
were cultured until 50% confluency. Medium was then
replaced by medium containing 0.1–0.5 lg/ml colcemid
(Sigma) and 0–0.01 lg/ml ethidium bromide and incubated
for 2–4 hr at 37C. Optimal conditions varied per cell line.
After incubation, cells were trypsinized and subsequently
treated with 0.075 M KCl for 10 min at 37C. Cells were
washed twice and fixed in methanol/acetic acid (3:1, v/v). FISH
probes were used for hybridization as outlined above, with
minor adjustments. Slides were only incubated for 8 min with
0.01% pepsin (800–1200 U/mg protein from porcine stomach
mucosa; Sigma) in 0.01N HCl at 37C. After washing, slides
were dehydrated in an ascending ethanol series and air dried.
Slides were then baked for 10 min at 56C. Postfixation was
performed in 4% formaldehyde in PBS for 10 min at RT. After
postfixation, the protocol was followed as described above.
Amplification of papillomavirus oncogene transcripts (APOT-
PCR). HPV oncogene transcripts were amplified as
described before.10,27 Briefly, reverse transcription was per-
formed using 25 lM oligo-(dT)17 primer coupled to a linker
sequence (dT)17-p3, 10 mM dNTPs each, 0.1 M DTT, 53
RT-buffer and SuperScript reverse transcriptase (Invitrogen,
Karlsruhe, Germany). Quality of cDNA was determined by a
standard GAPDH gene PCR. First-strand cDNAs containing
viral oncogene sequences were subsequently amplified with
semi-nested PCR using HPV-E7 specific 50-primers and oli-
go(dT) and adaptor primers (30). PCR products were sepa-
rated on a 1.2% agarose gel. All bands were cut out, purified
(QIAGEN Gel extraction kit, QIAGEN, Hilden, Germany)
and sequenced (GATC Biotech, Konstanz, Germany).
Sequence results were analyzed using the BLASTN program31
and further mapped using map viewer, both provided by the
National Center for Biotechnology Information (NCBI).25
Detection of integrated papillomavirus sequences (DIPS-PCR).
Integrated papillomavirus sequences were detected using the
Detection of Integrated Papillomavirus Sequences-PCR
(DIPS-PCR) assay, as described earlier.27,32 Briefly, genomic
DNA was digested using the Sau3AI restriction enzyme and
an enzyme-specific adapter was ligated to the restriction-
digested DNA using T4 DNA ligase (Roche Diagnostics,
Mannheim, Germany). Linear PCR was performed using five
HPV16 specific forward primers in independent setups. All
independent PCRs were followed by individual exponential
PCRs using further virus-specific forward primers and the
AP1 reverse primer. PCR products were separated on a 1.2%
agarose gel and products of interest were excised and subse-
quently sequenced (GATC Biotech). Sequence results were
analyzed using the BLASTN program31 and further mapped
using map viewer, both provided by the NCBI.25
mRNA expression of HPV16 E2, E6 and E7 and human EGFR
RNA was reverse transcribed using the iScript cDNA Synthesis
Kit (BioRad Laboratories, Hercules, CA). Real-time PCR reac-
tions were performed using SensiMix SYBR & Fluorescein (GC
Biotech, Alphen a/d Rijn, The Netherlands). The detection of the
housekeeping gene hypoxanthine phosphoribosyltransferase
(HPRT) was used for normalization of mRNA levels. Primer
sequences for HPRT were kindly provided by Prof. Dr. L. Hof-
land from Erasmus Medical Centre, Rotterdam, The Netherlands.
The following primers, synthesized by Biolegio BV, were used:
Target Primer Sequence Ref
HPV16
E2
Forward 50-TGATAGTACAGACCTACGTGACC
ATATAGA-30
Reverse 50-ATTACAAGGCCAGAGAAATGGG-30
HPV16
E6
Forward 50-CAGTTATGCACAGAGCTGCAA-30 33
Reverse 50-ATGACTTTGCTTTTCGGGATT-30
HPV16
E7
Forward 50-AGAGGAGGAGGATGAAATA
GATGGT-30
Reverse 50-CAATATTGTAACCTTTTGTTGCA
AGTG-30
EGFR Forward 50-CCAAGGGAGTTTGTGGAGAA-30
Reverse 50-CTTCCAGACCAGGGTGTTGT-30
HPRT Forward 50-CACTGGCAAAACAATGCAGACT-30 34
Reverse 50-GTCTGGCTTATATCCAACACTTCGT-30
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Figure 1. Representative examples of p16INK4A staining in cell lines UD-SCC-2 (HPV16 positive) and UPCI:SCC003 (HPV-negative). HPV16-
specific PCR. Lane 1 shows the 100, 200, and 300 bp fragments of a 100 bp ladder for fragment size determination, lane 2–12 show the results
of the HPV16 specific PCR. Lane 2: UD-SCC-2; lane 3: UM-SCC-047; lane 4: UPCI:SCC090; lane 5: UM-SCC-104; lane 6: UPCI:SCC152; lane 7:
UPCI:SCC154; lane 8: U2OS cell line with the empty pJ4X-vector as negative control; lane 9: 93VU147T; lane 10: HeLa (HPV18 cervix carcinoma
cell line); lane 11: CaSki (HPV16 positive cervix carcinoma cell line); lane 12: water. HPV16 FISH staining pattern in the seven cell lines. HPV16
was detected using a FITC-labeled probe (green) and cell nuclei are stained with DAPI (blue). Colocalization of FITC-labelled HPV16 probes
(green) with TRITC-labeled BAC clones (red) on interphase nuclei of UD-SCC-2 (BAC clone RP11–212B22), UM-SCC-047 (BAC clone RP11–
373I6), UPCI:SCC090 and UPCI:SCC152 (BAC clone RP11–23B15 for both), UPCI:SCC154 (BAC clone RP11-10J13) and 93VU147T (BAC clones
RP11–1331M22 and RP11–365D23, respectively). Colocalisation of HPV16 probes with probes for CEPX (green), CEP3 (green) or CEP9 (red) on
metaphase spreads of UD-SCC-2, UM-SCC-047 and UPCI:SCC090, respectively. Images of HPV16-E2 protein expression in U2OS cells with E2
containing pJ4X-vector (positive control; left), U2OS cells with empty pJ4X-vector (negative control; middle), and 93VU147T cell line (right),
showing diffuse nuclear immunostaining, no staining and numerous immunostained nuclear foci, respectively. Counterstaining was done with
Haematoxylin. Images of HPV16 RNA FISH on UD-SCC-2 (left) and UM-SCC-104 (right) cell lines showing variable numbers of transcriptionally
active integration sites (red signals) in DAPI counterstained nuclei (blue).
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Immunohistochemistry for HPV16 E2
CytoRichRed-fixed (3 mM), paraffin-embedded slides were
used for immunohistochemistry. The slides were deparaffi-
nized using xylol, rehydrated in a descending ethanol series
and pretreated with citrate buffer pH 6.1 (DAKO, EnVision
FLEX Target Retrieval Solution, Low pH) for 10 min at
97C. Primary mouse monoclonal anti-HPV16-E2 antibody
(Clone TVG 261; 1:100, Merck Millipore Corporation,
Amsterdam, The Netherlands) was added to the slides and
incubated for 1 hr at RT, followed by incubation with
FLEX1 Mouse LINKER (DAKO) for 20 min at RT and
EnVision FLEX/HRP (DAKO) for 30 min at RT. HRP was
visualized using DAB1 Chromogen (DAKO) substrate.
Between all of the incubation steps, the slides were washed
with wash buffer (DAKO). Finally, slides were counterstained
with hematoxylin, dehydrated and mounted in Vectashield
(Vector). Images were recorded in the brightfield mode using
the microscope described above.
Results
Active HPV16 infection is present in all cell lines
All cell lines have been tested for active HPV16 infection using
the algorithm suggested previously.4 AgarCyto blocks of the
cell lines showed overexpression of the CDK-inhibitor
p16INK4A using immunocytochemistry, which is routinely used
as a surrogate marker for HPV infection (see Fig. 1a). Further-
more, the presence of HPV16 DNA has been shown by PCR,
first using the consensus primers GP51/61 and subsequently
by using type-specific primers for HPV16 and 18 (see Fig. 1b).
RT-PCR analysis of the viral oncogenes E6 and E7 showed viral
gene expression in all cell lines (see below).
Viral load
HPV16 load in all cell lines was estimated using PCR and
was expressed as the number of HPV16 copies per b-globin
copy. Viral load varied from 1 (UM-SCC-104) up to 739
(UPCI:SCC090) HPV16 copies per human b-globin gene
copy (see Table 2).
DNA FISH integration analysis
All cell lines were tested for the presence of HPV16 DNA
using FISH on 70% ethanol suspensions and they all showed a
reproducible punctate nuclear signal, which indicates viral
integration. Each cell line showed a specific number of FISH
signals per nucleus, ranging from 2 (UD-SCC-2 and
UPCI:SCC154) to 7 (93VU147T) (Fig. 1c). UPCI:SCC090 and
2152, derived from the same patient, showed identical spot
numbers. UM-SCC-104, however, showed a variable number
of signals per nucleus, ranging from 1 to 4 (Table 2). Notably,
cell lines with a high viral load exhibited a higher number and/
or more intense FISH signals (see Fig. 1c and Table 2) and
showed stronger HPV16-specific PCR bands on agarose gel
(see Fig. 1b). Possible hybridization to RNA transcripts was
excluded by treating the cells with RNAse in a control
experiment.Ta
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Identification of HPV16 integration sites by PCR
APOT-PCR, a PCR-based method that can amplify both
viral-human fusion transcripts as well as episome-derived
viral transcript, was used to identify the site of viral integra-
tion in the cellular genome. A single integration site was
identified in five cell lines (UM-SCC-047, UPCI:SCC090,
UPCI:SCC152, UPCI:SCC154 and 93VU147T; see Table 3).
Sequencing analysis of the obtained viral-human fusion tran-
scripts revealed viral integration in 3 genes and in 2 inter-
genic regions. The protein-coding regions identified were
DIAPH2, exon 21 (UD-SCC-2), TP63 exon 7 (3q28, UM-
SCC-047) and NAP1 exon 4 (9q22.33, UPCISCC:090 and
UPCI:SCC152; both derived from two subsequently diag-
nosed recurrent tumors from the same patient). The inter-
genic regions identified were located on chromosomes 17q12
(93VU147T) and 21q11.2 (UPCI:SCC154).
All fusion transcripts detected by APOT-PCR showed
type A splicing as described by Klaes et al.10 from viral
nucleotide 880 directly into the human sequence in sense ori-
entation with the identified gene. Interestingly, only episomal
transcripts could be identified in the UM-SCC-104 cell line,
suggesting the presence of complete episomes, either inte-
grated or extrachromosomal. DIPS-PCR was performed to
verify the identified integration sites and to search for possi-
ble viral-human fusion products in the cell line where no
fusion transcript could be identified using APOT-PCR (UM-
SCC-104). No fusion product could be amplified in this cell
line, although the presence of episomal viral copies was con-
firmed. In the remaining cell lines the integration sequences
identified using APOT-PCR were confirmed by DIPS-PCR.
DIPS-PCR identified the integration site in the UPCI:SCC154
cell line to be located within the NRIP1 gene. Identified inte-
gration sites are summarized in Table 3.
To confirm that the identified human sequences were
localized adjacent to the viral genome, double-target FISH
analysis was performed using both the HPV16 probe and
BAC-probes complementary to the putative integration
sequence (see Fig. 1d). BAC-probes were shown to colocalize
with all HPV16 signals in two cell lines (UM-SCC-047 and
UPCI:SCC154). In three additional cell lines, HPV16 signals
were also detected without colocalization with the BAC-
probe (UPCI:SCC090, UPCI:SCC152 and 93VU147T).
HPV mapping on metaphase preparations
For the cell lines in which the integration loci did not coloc-
alize to a BAC-probe (UM-SCC-104, UPCI:SCC090 and
93VU147T), HPV16 FISH analysis in combination with kar-
yotyping based on inverted DAPI staining was performed on
metaphase preparations. All data are summarized in Table 2.
In the UPCI:SCC090 cell line additional integration events
were mapped to chromosomes 3 and 6, which is in agree-
ment with published data.35,36 Interestingly, in the metaphase
preparations of the UM-SCC-104 cell line, metaphase chro-
mosomes did not show HPV16 FISH signals, whereas inter-
phase cells, also present in the preparation, did show a
nuclear FISH staining pattern similar to the staining on 70%
ethanol suspensions (see Fig. 1c). This was shown in repeated
experiments with different observers (JvLA, E-JS and NO).
Although this might be a sensitivity issue, another explana-
tion might be that the virus is extrachromosomal, which is
supported by the detection of only episomal transcripts by
APOT- and DIPS-PCR (see above).
Integration events and ploidy status
To determine whether multiple colocalizing FISH-signals
indicated duplication or translocation of the involved chro-
mosome, double-target FISH was performed on metaphase
preparations of the cell lines, using both a CEP-probe as well
as an HPV probe. This showed that integration can be fol-
lowed by deletion of the sister chromosome and duplication
(UD-SCC-2) or multiplication (UM-SCC-047) of the chro-
mosome containing HPV integration, with all respective
chromosomes showing signals for both the CEP-probe as
well as the HPV16 probe. Duplication of chromosomes with
concurrent duplication of the sister chromosome was also
seen (UPCI:SCC090, UPCI:SCC152), shown by the presence
of chromosomes containing only a signal for the CEP-probe
as well as chromosomes containing signals for both CEP-
and HPV16 probes. Lastly, duplication could also be accom-
panied by translocation of a small portion of the involved
chromosome to a different chromosome (UM-SCC-047).
The detected multiplication of chromosomes is in line
with the ploidy status of the different cell lines, which in six
of the seven cell lines showed copy number variations for
chromosomes 1 and 7, a hallmark for chromosomal instabil-
ity and aneusomy8 (Table 2).
Gene expression of HPV16 E2, E6 and E7 and human EGFR
To determine whether integration affects the expression of
the viral genes, the expression levels of the viral genes E2, E6
and E7 were determined using RT-PCR (see Fig. 2). Expres-
sion of the viral gene E2, which is known to regulate gene
transcription of the oncogenes E6 and E7, was present at
variable levels in six of the seven cell lines. To verify the
presence of HPV16-E2 protein expression, we carried out
immunohistochemistry on tissue sections of five CytoRichRed
fixed and paraffin embedded cell lines, a positive control
(U2OS cell line transfected with E2) and a negative control
(U2OS cell line transfected with empty pJ4X-vector; Fig. 1f).
U2OS E2 cells showed a strong diffuse nuclear immunostain-
ing in all cells. U2OS vector cells and the UM-SCC104 cell
line were negative and the cell lines UPCI:SCC090,
93VU147T, UD-SCC-2, UM-SCC47 showed E2 positive foci
in the nuclei at a frequency of 43, 9, 2 and 0.5%, respectively.
mRNA expression of the viral oncogenes E6 and E7 could be
detected in all cell lines at variable levels, but no correlation
could be found with the levels of E2 mRNA expression.
No correlation was found between the number of FISH
HPV16 signals, viral load and viral mRNA gene expression.
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To verify if all DNA-FISH detected HPV16 integration sites
are transcriptionally active, we performed RNA FISH (see
Supporting Information Table S1). These data showed that
there is a variation of transcriptionally active sites within dif-
ferent cells of each cell line ranging from the maximum
number of viral integration signals up to zero. To ensure that
this variation was not the result of incomplete cells due to
the cutting of tissue sections, we also performed RNA FISH
on 70% ethanol suspensions leading to comparable results
(data not shown).
In addition, the level of EGFR expression was examined
for each of the seven cell lines. This showed variable expres-
sion of 0.4 (UPCI:SCC090) up to 5.6-fold (UM-SCC-104)
expression to HPRT. As the median EGFR expression in 61
primary HPV-associated HNSCC is 0.3 fold to HPRT (range
0.001–18.6-fold to HPRT, unpublished results), this indicates
increased expression of EGFR in all cell lines.
Discussion
HR-HPV infection is a well-established risk factor contribut-
ing to the development of HNSCC, particularly OSCC. HPV-
positive tumors have different clinical and pathobiological
characteristics, including a better prognosis as compared to
HPV-negative tumors.4 It is still under debate, which factors,
in addition to the presence of HPV DNA and the resulting
viral gene expression in the host cell, are contributing to
tumor development and progression. For example, integra-
tion of the viral DNA into the host genome and the resulting
disruption of invaded genes might play an important role in
the process of HPV carcinogenesis, as seen in HPV-
associated cervical cancer. In the case of HNSCC, few studies
have addressed this highly relevant issue.26,36–39
Since in vitro testing is still an important step in the
development of new therapeutic options, it is imperative to
be able to study well-established cell line models for HPV-
positive HNSCC. In the underlying study, HPV16-associated
parameters, such as viral load and integration, have been
assessed in seven established HNSCC cell lines, shown to be
HPV-induced by p16INK4A immunostaining and HPV-type-
specific PCR.
Integration of HPV DNA was detected in six of the seven
cell lines using three independent methods, i.e. APOT- and
DIPS-PCR and FISH, which all gave concurrent results with
respect to the integration locus. Furthermore, for three cell
lines (UD-SCC-2, UM-SCC-47 and UPCI:SCC090) our
results confirmed previously reported integration sites.35,36
Two cell lines that were derived from the same patient
(UPCI:SCC090 and UPCI:SCC152), showed identical integra-
tion sites despite the fact that they were established from
biopsies taken from different locations and at different time
points, indicating clonal expansion of the tumor. One cell
line (UM-SCC-104) did not show integration, but rather the
presence of extrachromosomal HPV DNA, as assessed by
APOT- and DIPS-PCR. This is in contrast to a recent study
by Akagi et al., suggesting viral integration in this cell line.36
However, in our opinion their presented FISH and Northern
blotting data on UM-SCC-104 did not provide sufficient evi-
dence for viral integration. We were unable to detect the
integrated virus DNA on metaphase chromosomes of the cell
line and it is very unlikely that we missed this integration
site by our DIPS- and APOT-PCR assay in the here pre-
sented study. Maybe the detected deletion in HPV16-E2 by
Akagi et al. using whole genome sequencing is present in epi-
somal DNA or alternatively viral integration or loss of the
integration site in UM-SCC-104 could be a result of
culturing.36
We detected viral loads varying from 1 up to 739 HPV16
copies per b-globin gene copy. In contrast to results obtained
from cervical malignancies,40 viral load did not seem to be
correlated to integration status. This can be concluded from
the two cell lines showing a viral load of 1 HPV DNA copy
per b-globin copy, one of which showed HPV DNA integra-
tion and the other showed only episomal HPV.
Cell lines with a higher viral load did exhibit strong punc-
tate FISH signals, indicating that the HPV genome may be
present in integrated tandem repeats. This assumption is sup-
ported by the finding that these strong signals are not derived
from RNA transcripts present at these loci, since RNAse
treatment before the DNA FISH analysis did not lead to a
substantial decrease in signal intensity (data not shown).
Moreover, the cell lines showed two up to seven HPV inte-
gration sites by FISH, whereas in primary tumors generally
only one signal per nucleus is detected.8 To determine
whether this is due to either multiplication of the integration
locus or a result of multiple independent integration events,
Figure 2. Expression of viral genes E2, E6, and E7 for each of the
seven cell lines. Expression levels are displayed as x-fold change
as compared with the expression of the housekeeping gene HPRT.
Expression of EGFR for each of the seven cell lines. Expression lev-
els are displayed as x-fold change as compared to the expression
of the housekeeping gene HPRT.
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cohybridization of HPV16 probes with a BAC-probe comple-
mentary to the identified integration sequences was performed.
In the cell lines UD-SCC-2, UM-SCC-047 and UPCI:SCC154
all HPV16 signals were shown to colocalize with the BAC-
probe, while in UPCI:SCC090, UPCI:SCC152 and 93VU147T
the BAC-probe colocalized with part of the HPV16 FISH sig-
nals. The presence of more than one colocalizing signal indi-
cates multiplication of the integration locus. Multiplication of
an existing integration site was furthermore shown by co-
hybridization of the HPV-probe with CEP-probes for the cor-
responding chromosome. For the UD-SCC-2 cell line, derived
from a male patient, the two HPV16 FISH signals were located
on two different CEPX-containing chromosomes, indicating
that a duplication event has occurred. In the UPCI:SCC090
four chromosome copies containing CEP9 were detected, of
which two harboured HPV16 signals, indicating duplication of
both copies of chromosome 9. In the UM-SCC-047 cell line,
five HPV16 signals were detected on five separate chromo-
somes, of which four also contained CEP3, indicating multipli-
cation of the initial integration site. The fifth chromosome
contained very strong HPV- and BAC-signals, but no CEP3
signal (see Fig. 1e), which might indicate that this chromo-
some evolved by a different mechanism, for example involving
both translocation of part of chromosome 3 and amplification
of the integration site. Figure 3 provides a schematic represen-
tation of the multiplication and translocation events identified
in the HNSCC cell lines indicated. This finding further sup-
ports the results of Akagi et al. that show that HPV integrants
may promote genomic instability.36
Besides HPV16 signals colocalizing with the BAC-probe in
UPCI:SCC090, UPCI:SCC152 and 93VU147T cell lines, addi-
tional HPV16 signals were detected. The non-colocalizing
HPV signals might indicate multiple independent integration
events, which were not detected by APOT- or DIPS-PCR. A
possible explanation for the fact that the APOT-PCR assay is
unable to detect all the different integration sequences may be
that (several of) these sequences are not actively transcribed
and therefore are not clinically relevant. However, the inability
of the DIPS-PCR assay to detect these integrated sequences
may come from an alternative integration mechanism that is
not detected by our PCR, which is based on E1 and E2 HPV
sequences. Using DIPS-PCR with additional primers covering
the entire HPV genome, Li et al.41 described a mechanism for
HPV16 integration in exfoliated cervical cells based on disrup-
tion of the L1 or L2 gene. These authors indicated that inte-
gration at these viral sites would normally not result in
progression to (pre)malignant lesions. It is therefore likely that
such integration events have occurred in our cell lines, before
or after the clinically relevant integration event took place.
From studies in cervical cancer it is known that viral load
does not necessarily correlate to expression levels of E6 and
E7.42 Similarly, in the HNSCC cell lines, as well as in primary
Figure 3. Schematic representation of the possible multiplication and translocation events in the cell lines. High-risk human papillomavirus
(HPV) infection is a well-established risk factor for head and HNSCC development. It is still unclear, however, whether viral DNA integration
into the host genome plays an important role in HPV carcinogenesis in HNSCC. In this study, seven HPV16-positive HNSCC cell lines
showed integrated and/or episomal viral DNA that is transcriptionally active. Both viral load and expression of several viral early genes
were variable. Because the cell lines also feature EGFR overexpression and aneusomy, which are parameters of poor prognosis, they may
represent suitable model systems for the development of new antiviral therapies.
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HNSCC, the variation in viral load was not reflected in the
expression of the viral genes E2, E6 and E7. Furthermore, the
current concept of cervical carcinogenesis suggests that HPV
integration leads to disruption of the viral genome in the E1
or E2 open reading frame (ORF), followed by loss of the E2
inhibitory gene function on E6 and E7 expression. Subse-
quently expression of both oncogenes is thought to be
enhanced.33,34,43 However, in the different HNSCC cell lines,
such a correlation could not be found. E2 mRNA and protein
levels were highly variable in UD-SCC-2, UM-SCC-47,
UPCI:SCC090, UPCI:SCC152 and 93VU147T, even though
integration was identified. A recent publication suggests that
HPV integration without concurrent loss of the E2 gene can
also occur in HNSCC resulting in viral concatenates in the
human genome.37 The high viral load in combination with a
limited number of strong FISH signals indicates that integra-
tion of such stretches of multiple HPV-copies could have
occurred in our cell lines as well. E6 and E7 mRNA levels
were equally variable in all cell lines and no correlation was
seen with the expression levels of E2. This is in agreement
with the results obtained in primary HNSCC, in which the
expression levels of E2, E6 and E7 mRNA transcripts were
highly variable and did not show correlation to the physical
status of the virus.8,27
In conclusion, we have characterized seven established
HPV16-positive HNSCC cell lines, which showed inte-
grated and/or episomal viral DNA that is transcriptionally
active. However, viral E2, E6 and E7 gene expression
proved to be independent of viral load and the number of
viral integration sites, suggesting that integration does not
affect viral gene expression. The analyzed cell lines, fur-
thermore, exhibit characteristics of primary HPV-positive
OSCC with a poor prognosis, such as EGFR overexpres-
sion and aneusomy,8,44,45 although it cannot be ruled out
completely that molecular changes may have accumulated
due to cell culturing. We believe that these cell lines rep-
resent suitable model systems of HPV-positive HNSCC
that respond poorly to current treatment modalities and
that they may be beneficial in future studies for the analy-
sis of new treatment options.
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